Autres langues Ipsen

Actions

IPN

FR0010259150

Produits pharmaceutiques

Temps réel Euronext Paris 16:08:54 18/08/2026			Varia. 5j.	Varia. 1 janv.
163,40 ^EUR	+1,18%		+5,15%	+37,31%

17/08	Ipsen : Kepler Cheuvreux neutre sur le dossier	ZM
04/08	Marengo Therapeutics, Inc. et Ipsen S.A. désignent un premier candidat-médicament dans le cadre de leur collaboration stratégique TriSTAR	CI

Autres langues

17/08	IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2026
10/08	IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2026
04/08	Marengo Therapeutics, Inc. and Ipsen S.A. Nominate First Drug Candidate Under Strategic Tristar Collaboration
03/08	IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2026
30/07	Ipsen S.A. publishes its 2026 Half-Year Report (half-year ended 30 June 2026)
30/07	Ipsen : Another quarterly beat; 2026 guidance upgraded
30/07	Ipsen S.A. Reports Earnings Results for the Half Year Ended June 30, 2026
30/07	Ipsen Raises FY26 Sales Growth Outlook
30/07	Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance
29/07	Ipsen nominates Catherine Bradley to its Board of Directors as independent Director
29/07	Ipsen Announces Appointment of Catherine Bradley, CBE, as an Independent Director, Chair of the Audit Committee and Member of the Compensation Committee, Effective July 29, 2026
27/07	IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2026
24/07	Healthcare Shares Benefit From Rotation Away From AI Darlings -- Health Care Roundup
24/07	Ipsen Provides Update On Phase III BOLD Trial In Biliary Atresia
24/07	Ipsen Says Phase 3 Trial of Bylvay in Biliary Atresia Misses Primary Endpoint
24/07	Ipsen provides update on Phase III BOLD trial in biliary atresia
22/07	Ipsen Closes Purchase of Potravitug Developer Memo Therapeutics
22/07	Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline
22/07	Ipsen S.A. acquired Memo Therapeutics AG.
21/07	IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2026
15/07	IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2026
14/07	Where would AI lead Pharma in the long run?
13/07	Ipsen : IQIRVO® demonstrates statistically significant improvement in ALP normalization in patients with PBC in Phase IIIb ELSPIRE study
10/07	Ipsen - Dysport is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine
09/07	Afternoon Meeting: Wall Street ignora las alarmas